Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MIN-102 (leriglitazone) is Minoryx’s novel orally bioavailable and selective PPARγ agonist with a potential first-in-class and best-in-class profile for adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy.
Product Name : MIN-102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2023
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with leriglitazone demonstrated PPARg engagement in all patients within the target range required for efficacy as assessed by a biomarker (adiponectin).
Product Name : MIN-102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : European Investment Bank
Deal Size : $29.0 million
Deal Type : Funding
Details : The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.
Product Name : MIN-102
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 30, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : European Investment Bank
Deal Size : $29.0 million
Deal Type : Funding
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Sperogenix Therapeutics
Deal Size : $78.0 million
Deal Type : Licensing Agreement
Details : Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Product Name : MIN-102
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Sperogenix Therapeutics
Deal Size : $78.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Perflutren,Immunoglobulin
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia
Details : Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.
Product Name : Albutein
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Perflutren,Immunoglobulin
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable